赢创公布二季度业绩并确认上调2026年全年EBITDA展望

U.S.-Iran talks uncertain; Palantir, Snap report - what’s moving markets
Introduction & Market Context
Evonik Industries (ETR:EVK) presented its second-quarter 2026 results on August 4, 2026, revealing what Chief Executive Christian Kullmann characterized as "the best quarter result in four years." The German specialty chemicals company significantly raised its full-year outlook following a 24% year-over-year surge in adjusted EBITDA to €630 million, driven by strong performance across its Advanced Technologies segment and improved market conditions in several key businesses.
The presentation, delivered by CEO Kullmann and CFO Michael Rauch, outlined a comprehensive strategic repositioning alongside the strong quarterly results. The company extended its "Evonik Tailor Made" efficiency program through 2029 and announced plans to reduce headcount by an additional 3,200 full-time equivalents beyond the 2,000 already targeted by year-end 2026.
Following the results, Evonik’s stock rose 2.42% to $18.015, trading near its 52-week high of $18.25 and reflecting investor confidence in the company’s improved trajectory.
Quarterly Performance Highlights
The company’s second-quarter performance exceeded expectations across multiple metrics, as illustrated in the following comprehensive financial overview:
Evonik reported sales of €3,893 million for the quarter, an 11% increase from €3,499 million in the prior-year period. The sales growth was balanced, with volume contributing 7 percentage points, price adding another 7 points, while foreign exchange headwinds reduced growth by 2 percentage points.
The standout metric was adjusted EBITDA, which reached €630 million compared to €509 million in Q2 2025. This 24% year-over-year increase marked a significant acceleration from the first quarter’s €475 million, pushing the EBITDA margin to 16.2% from 14.5% a year earlier.
The quarterly EBITDA performance and margin expansion is detailed in the following chart:
The company attributed the strong Q2 performance to several key drivers: solid Custom Solutions performance with 7% year-over-year growth, exceptional Advanced Technologies results up 25% year-over-year, higher spreads in the Oxeno C4 business, and ongoing benefits from optimization programs across the group.
Free cash flow showed dramatic improvement, turning positive at €49 million compared to negative €211 million in the prior-year quarter, as shown in this cash flow analysis:
The cash flow turnaround was driven by better earnings, reduced bonus payouts, and strict net working capital management. For the first half of 2026, free cash flow reached €232 million versus negative €16 million in the prior-year period, despite only a 3% increase in adjusted EBITDA.
Segment Performance Deep Dive
The Advanced Technologies segment emerged as the primary growth driver, delivering exceptional results that exceeded management’s expectations. The following breakdown illustrates the segment’s strong performance:
Advanced Technologies posted sales of €1,647 million, up 9% year-over-year, with adjusted EBITDA surging 25% to €333 million. The EBITDA margin expanded to 20.2% from 17.6% in the prior-year quarter. Within the segment, Organics showed particularly strong performance, with High Performance Polymers benefiting from higher capacity utilization following a major shutdown last year, and Crosslinkers capitalizing on favorable market momentum. Animal Nutrition demonstrated ongoing strong price momentum, though volumes were slightly constrained by planned shutdowns.
The Custom Solutions segment delivered steady results, as detailed in this performance overview:
Custom Solutions generated sales of €1,422 million, up 4% year-over-year, with adjusted EBITDA rising 7% to €271 million and margins improving to 19.1%. The Additives business benefited from elevated demand, partly due to war-related supply chain disruptions, while the Care segment saw favorable price realization in specialties compensate for weak volumes in base ingredients.
The Infrastructure and Other segment showed remarkable improvement, particularly in the C4 business, which benefited from higher margins related to Middle East geopolitical disruptions. Infrastructure adjusted EBITDA jumped 163% year-over-year to €100 million, though this was partially offset by higher bonus provisions in the "Other" category.
Strategic Initiatives and Efficiency Programs
Evonik’s strategic framework centers on controlling its destiny despite challenging market conditions, as outlined in this strategic positioning slide:
The company articulated a clear path forward, emphasizing its position of strength characterized by industry-leading cash generation and moderate leverage. Looking ahead, management outlined plans for consistent cost reduction, further portfolio optimization, growth in attractive niches, and more balanced use of cash, targeting a return on capital employed (ROCE) of approximately 11% "as soon as possible," with tangible progress expected in 2026.
The centerpiece of Evonik’s transformation is the expanded "Evonik Tailor Made" efficiency program, detailed comprehensively in the following chart:
The program, originally launched in 2023 and now extended through 2029, targets total workforce reductions of approximately 5,200 full-time equivalents. The company has already reduced headcount from 31,930 in 2024 to an estimated 30,000 by year-end 2026, with an additional 3,200 FTE reductions planned from 2027-2029. The extended program will bundle all cost savings and optimization measures for more efficient steering, apply a holistic view covering both administrative and operative roles, and leverage increased efficiency through digitalization.
For the initial 2023-2026 phase, Evonik expects €400 million in gross savings from the program, with 80% related to personnel costs. A provision of €238 million was booked in Q2 2024 for the first 2,000 employee reductions.
The company is also executing targeted business optimization programs across six key areas, as shown in this detailed program overview:
These initiatives span Amino Acids, High Performance Polymers, Silica/Silanes, Coating & Adhesive Resins, Health Care, and Crosslinkers, with all programs currently in execution phase. Key actions include site closures (Witten, Hanau, Havre de Grace, Waterford, Leverkusen), production optimization, portfolio rationalization, and operational cost reduction, with full savings expected by end of 2027.
Innovation and Growth Investments
Despite the efficiency focus, Evonik continues investing in innovation across three strategic growth areas, as illustrated in this product showcase:
The company highlighted market-ready solutions in Advanced Precision Biosolutions (Ecobiol probiotics for livestock), Circular Economy enablement (specialized catalysts and adsorbents for chemical recycling), and Energy Transition acceleration (DURAION membranes for cost-efficient green hydrogen production via water electrolysis).
Financial Position and Cash Flow
The company’s balance sheet evolution through the first half of 2026 is detailed in this net debt waterfall chart:
Net financial debt increased from €3,311 million at year-end 2025 to €3,620 million at mid-year 2026, primarily due to the €466 million dividend payout. Operating cash flow of €636 million was partially offset by €404 million in capital expenditures and €45 million in net interest payments.
The company’s leverage metrics and pension position are tracked in this multi-year comparison:
Total leverage stood at 2.6x at mid-year 2026, up slightly from 2.4x at year-end 2025, while net financial debt leverage remained stable at 1.8x. Pension provisions increased modestly to €1,538 million despite a slightly lower discount rate, with plan assets showing positive development. The company maintains a solid funding ratio of approximately 85% for its long-dated pension obligations.
Raised Full-Year Outlook
Based on the strong first-half performance, Evonik significantly raised its full-year 2026 guidance, as shown in this outlook comparison:
The company now expects adjusted EBITDA of €2.0 billion to €2.2 billion for full-year 2026, up from the previous guidance range of €1.7 billion to €2.0 billion. This represents a €250 million increase at the midpoint. By segment, Custom Solutions is expected to remain stable at prior-year levels (2025: €909 million), Advanced Technologies is projected considerably above prior year (2025: €944 million), and Infrastructure including C4 is forecast significantly above prior year (2025: €21 million).
The company confirmed its free cash flow outlook with approximately 40% conversion for 2026, as detailed in this cash flow guidance:
The building blocks for free cash flow development include better operating results, disciplined capital expenditure, lower bonus payments for 2025, and some headwind from net working capital inflation.
Additional financial guidance metrics for the full year are provided in this comprehensive table:
Key updates include sales expectations of around €15 billion (up from previous guidance of €13.5-14.5 billion), ROCE slightly above prior-year level (2025: 6.1%), capital expenditure of approximately €750 million, and an adjusted tax rate of around 25% (down from the long-term sustainable level of 30% previously guided).
Detailed Financial Statements
The complete adjusted income statement for the quarter shows the profit progression:
Adjusted EBIT reached €370 million, up 48% from €250 million in the prior-year quarter. After adjusting for net financial results and a lower-than-expected tax rate of 18%, adjusted net income surged 85% to €296 million, translating to adjusted earnings per share of €0.65 versus €0.34 in Q2 2025. The quarter included €207 million in adjustments, comprising €48 million for restructuring (primarily the Witten site closure provision) and €159 million for other special items (mainly impairment of the Oxeno C4 business).
The cash flow statement reveals the drivers of improved liquidity:
Cash flow from operating activities improved dramatically to €229 million from negative €35 million in the prior-year quarter, driven by strict net working capital management (outflow of €180 million versus €237 million last year) and lower outflows for bonuses combined with higher non-cash provisions. After capital expenditures of €180 million, free cash flow turned positive at €49 million.
The quarterly segment performance trends are tracked in this comprehensive overview:
This detailed breakdown shows the progression of sales and adjusted EBITDA across all segments for each quarter from Q1 2025 through Q2 2026, providing visibility into the improving trend, particularly in Advanced Technologies and Infrastructure.
Forward-Looking Statements
While raising full-year guidance, management maintained a balanced perspective on the remainder of 2026. The presentation emphasized that with €1.1 billion of adjusted EBITDA already delivered in the first half, the company needs approximately €1 billion in the second half to reach the midpoint of its upgraded outlook range.
The company expects the third quarter to remain strong, potentially matching or slightly exceeding Q2 performance levels, with methionine anticipated to be the strongest contributor. However, management indicated expectations for a more pronounced normalization in the fourth quarter, reflecting typical seasonal patterns and the potential moderation of some favorable market conditions that benefited the first half.
Evonik confirmed that its restructuring program remains on track, with divestitures of Oxeno and SYNEQT proceeding as scheduled. The company reiterated its commitment to delivering on efficiency targets while maintaining disciplined capital allocation, with cash directed toward organic investment and dividends rather than share buybacks in the near term.
The presentation underscored management’s view that despite near-term strength, structural headwinds persist in the chemical sector, requiring continued focus on cost optimization, portfolio refinement, and strategic positioning in attractive niche markets where Evonik can leverage its integrated production network and technical expertise.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.